"Biomarkers can be challenging to understand in CIDP because of the rarity and heterogeneity of the disease," said Jeffrey ...

Q3 2024 Management View CEO Matt Gline highlighted 2025 as a year of major milestones, focusing on validating the anti-FcRn franchise with upcoming MG and CIDP data and a central registrational ...

Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase) is the first drug in the FcRn blocker class to treat CIDP, a rare autoimmune disease of the peripheral nervous system that causes fatigue ...

In 2024, the Food and Drug Administration (FDA) approved Vyvgart Hytrulo, a new effective treatment for CIDP in adults. Vyvgart Hytrulo works by reducing the level of pathogenic (disease-causing ...

Background: Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immune-mediated progressive or relapsing disorder causing peripheral neuropathic disease of duration more ...

Immunovant anticipates initiating clinical trials evaluating IMVT-1402 in a total of ten indications by March 31, 2026. Neurology Program: ...

(RTTNews) - argenx SE (ARGX) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy. VYVDURA is ...

We are positioned for significant expansion in 2025 with the FDA decision on approval of our pre-filled syringe, global CIDP rollout ... treatment of autoimmune diseases. Through this vision ...

This systematic review demonstrated that IVIg and corticosteroids still provide the most effective first line treatment options for patients with active CIDP. The review also revealed there is a ...

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...